Caladrius Biosciences to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call on Thursday, March 5, 2020 ...
February 27 2020 - 8:30AM
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the
“Company”), a late-stage therapeutics development biopharmaceutical
company pioneering advancements of cell therapies in select
cardiovascular and autoimmune diseases, today announced that it
will report financial results for the three and twelve months ended
December 31, 2019 after the close of the U.S. financial markets on
Thursday, March 5, 2020. The Company will host a live conference
call and audio webcast to discuss the financial results and provide
a general business update at 4:30 p.m. Eastern time.
Shareholders and other interested parties may participate on the
conference call by dialing (866) 595-8403 (U.S.) or (706) 758-9979
(International), using the conference ID code: 4155934. The live
webcast will be accessible via the Events page listed under the
Investor section of the Company’s website at
www.caladrius.com/investors/news-events/events.
For those unable to participate on the live conference call, an
audio replay will be available approximately two hours after the
conclusion of the call until 11:59 p.m. ET on March 12, 2020. To
access the replay, please dial (855) 859-2056 (U.S.) or (404)
537-3406 (International) and provide the conference ID code:
4155934.
A webcast replay of the conference call will remain available on
the Company’s website for 90 days.
About Caladrius BiosciencesCaladrius is a
late-stage therapeutics development biopharmaceutical company
pioneering advancements of cell therapies for select cardiovascular
and autoimmune diseases. Our leadership team collectively has
decades of biopharmaceutical development experience and
world-recognized scientific achievement in the fields of
cardiovascular and autoimmune disease, among other areas. Our
current product candidates include three developmental treatments
for cardiovascular diseases based on our CD34+ cell therapy
platform: CLBS12, recipient of a SAKIGAKE designation in Japan and
advanced therapy medicinal product classification (ATMP) in Europe,
eligible for early conditional approval for the treatment of
critical limb ischemia in Japan based on an ongoing clinical trial;
CLBS16, subject of the proof-of-concept ESCaPE-CMD clinical trial
in the U.S.A. for the treatment of coronary microvascular
dysfunction; and CLBS14, a Phase 3 ready clinical program in no
option refractory disabling angina and recipient of a RMAT
designation in the U.S.A. For more information on the company,
please visit www.caladrius.com.
Contact:
Investors: Caladrius Biosciences, Inc. John Menditto Vice
President, Investor Relations and Corporate Communications
Phone: +1-908-842-0084 Email: jmenditto@caladrius.com
Media: W2O Group Christiana Pascale Phone: +1-212-257-6722
Email: cpascale@w2ogroup.com
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Sep 2023 to Sep 2024